VantAI Appoints Jae Won Kim as Chief Operating Officer and Chief Financial Officer

NEW YORK–(BUSINESS WIRE)–VantAI, a leader in generative AI and drug discovery, announced the appointment of Jae Won Kim as Chief Operating Officer (COO) and Chief Financial Officer (CFO). Ms. Kim is an experienced finance, corporate development, and operations executive with a strong track record, especially in drug discovery and the induced proximity landscape. Having led one of the largest deals in induced proximity history, she brings over 15 years of deal making experience to VantAI and its mission.

“This is a company that will fundamentally change how drugs are developed across multiple therapeutic areas. I look forward to working with this group of innovators.”Post this

Ms. Kim joins VantAI from Orum Therapeutics, a clinical-stage private biotechnology company, where she served as CFO and played a pivotal role in the sale of ORM-6151, a first-in-class, anti-CD33 antibody-enabled GSPT1 degrader, to Bristol Myers Squibb.

Prior to Orum, Ms. Kim served as a Director in the Healthcare Investment Banking Group at Citigroup, where she advised on a wide range of transactions, including mergers and acquisitions, equity and debt offerings, and strategic partnerships. Ms. Kim earned a BBA in business administration and a BA in English literature at Korea University in Seoul, South Korea, and a JD-MBA at Northwestern University in Chicago.

As COO/CFO of VantAI, Ms. Kim will oversee the company’s operations, including finance, legal and corporate development functions. She will also work closely with the CEO and the board of directors to shape the company’s strategic direction, including new disruptive business models, external communications, and growth plans.

“VantAI prides itself on attracting exceptional talent, and Jae is a standout embodiment. Her unparalleled blend of experience and expertise makes her the ideal choice to lead us through the exploration of groundbreaking new business models,” said Zach Carpenter, VantAI’s Founder and CEO. “With a decade of innovation in healthcare and pharmaceutical finance, serving as CFO of a pioneering degrader company that established ADC targeting degraders as a key player, and orchestrating the largest deal in the industry’s history, Jae’s credentials are unmatched. We are excited to welcome her aboard our mission, confident that her leadership will propel us to new heights.”

“I am thrilled to join this incredible team at VantAI at this exciting time,” said Ms. Kim. “This is a company that will fundamentally change how drugs are developed across multiple therapeutic areas. I look forward to working with this group of innovators.”

About VantAI

VantAI is at the forefront of applying artificial intelligence technologies to drug discovery. With a cross-disciplinary team of world-class scientists and engineers, VantAI is uniquely suited to power a best-in-class solution for proximity modulation, where the nuance of protein-protein interactions, such as those in protein degradation, has outsized influence on drug success. VantAI has collaborated with and achieved milestones for numerous leading biopharma partners on difficult to drug targets leading to the launch of new development programs with exciting properties. For more information, please visit www.vant.ai.